Cancer Drug Resistance
Overview
Cancer Drug Resistance is a scientific journal, published since 2018 in English. The journal's country of origin is United States.
Details
Details
Abbr.
Cancer Drug Resist
Start
2018
End
Continuing
Frequency
Quarterly
e-ISSN
2578-532X
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 11552
24
SJR / Ranks: 3587
1035
CiteScore / Ranks: 4374
5.50
Recent Articles
1.
Zhang Y, Ma Y, Ma E, Chen X, Zhang Y, Yin B, et al.
Cancer Drug Resist
. 2025 Mar;
8:10.
PMID: 40051497
Hepatocellular carcinoma (HCC) remains a serious threat to global health, with rising incidence and mortality rates. Therapeutic options for advanced HCC are quite limited, and the overall prognosis remains poor....
2.
Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H
Cancer Drug Resist
. 2025 Mar;
8:7.
PMID: 40051496
Metabolic reprogramming within the tumor microenvironment (TME) plays a critical role in driving drug resistance in gastrointestinal cancers (GI), particularly through the pathways of fatty acid oxidation and glycolysis. Cancer...
3.
Khorasanchi A, Hong F, Yang Y, Singer E, Wang P, Li M, et al.
Cancer Drug Resist
. 2025 Mar;
8:9.
PMID: 40051495
Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers a uniquely comprehensive and integrative...
4.
Chen Y, Tan J, Gao L, Yang J, Huang J, Yang J, et al.
Cancer Drug Resist
. 2025 Mar;
8:8.
PMID: 40051494
Small-cell lung cancer (SCLC) is usually diagnosed as an advanced stage with a poor outcome. SCLC has limited response to immunotherapy due to the absence or lack of immune cell...
5.
Biersack B, Nitzsche B, Hopfner M
Cancer Drug Resist
. 2025 Feb;
8:6.
PMID: 39935431
Small-molecule BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK (MAPK/ERK) kinases inhibitors (e.g., trametinib) have distinctly improved the survival of patients suffering from BRAF-mutant cancers such as melanomas. However, the...
6.
Yang Y, Yu S, Liu W, Zhuo Y, Qu C, Zeng Y
Cancer Drug Resist
. 2025 Feb;
8:1.
PMID: 39935430
Ferroptosis is an iron-dependent form of programmed cell death induced by lipid peroxidation. This process is regulated by signaling pathways associated with redox balance, iron metabolism, and lipid metabolism. Cancer...
7.
Chen Z, Mei K, Tan F, Zhou Y, Du H, Wang M, et al.
Cancer Drug Resist
. 2025 Feb;
8:3.
PMID: 39935429
Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer (NSCLC), presents significant clinical challenges due to its high mortality and limited therapeutic options. The molecular heterogeneity and...
8.
Zhang H, Tang H, Tu W, Peng F
Cancer Drug Resist
. 2025 Feb;
8:4.
PMID: 39935428
Gastrointestinal (GI) cancers are becoming a growing cause of morbidity and mortality globally, posing a significant risk to human life and health. The main treatment for this kind of cancer...
9.
Xie J, Lin X, Deng X, Tang H, Zou Y, Chen W, et al.
Cancer Drug Resist
. 2025 Feb;
8:2.
PMID: 39935427
Cancer-associated fibroblasts (CAFs) constitute a critical component of the tumor microenvironment (TME). CAFs can be reprogrammed by cancer cells, leading to the production of extracellular vesicles (EVs). These EVs serve...
10.
Cejalvo Andujar J, Ayala de la Pena F, Margeli Vila M, Pascual J, Tolosa P, Pages C, et al.
Cancer Drug Resist
. 2025 Feb;
8:5.
PMID: 39935426
This review offers an expert perspective on biomarkers, CDK4/6 inhibitor efficacy, and therapeutic approaches for managing hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-) advanced breast cancer (ABC), particularly...